Relmada Therapeutics, a Blue Bell, PA-based clinical-stage company developing novel therapies for the treatment of chronic pain today, has raised $3m in an initial close of its Series A financing.
Noteholders BioAdvance and Ben Franklin Technology Partners of Southeastern Pennsylvania, as well as, equity investor Wonpung Mulsan Co., Ltd, have converted their existing liens into the Series A Convertible Preferred Stock.
Led by Sergio Traversa, CEO, Najib Babul, PharmD, President and CSO, and Danny Kao, PhD, JD, Consulting Senior Vice President, Pharmaceutical Development, Relmada is advancing LevoCap, a new tool to treat chronic pain where non-opioids or other opioids do not provide adequate relief. It is a once-a-day extended release dosage form of the potent opioid levorphanol in a tamper resistant delivery system and for general corporate activities.
The company intends to use the capital to continue the development of LevoCap.
FinSMEs
24/07/2012
{ 1 comment… read it below or add one }
Excellent thinking. Wondering what you think of its implication on society as a complete though? You can find times when things like this begin to have global expansion and frustration. Ill be about soon to look at your response….